查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1876156

核酸內切酶市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Endonucleases Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

核酸內切酶市場成長驅動因子

全球核酸內切酶市場正經歷強勁成長，主要得益於基因組研究、基因編輯技術和個人化醫療的快速發展。根據 Fortune Business Insights 預測，該市場規模預計將在 2024 年達到 3.571 億美元，並在 2025 年達到 3.903 億美元。預計到 2032 年，該市場規模將進一步成長至 7.286 億美元，在預測期（2025-2032 年）內，複合年增長率 (CAGR) 為 9.32%。北美預計將在 2024 年以 47.61% 的市場佔有率引領市場，這主要得益於其高額的研發投入、先進的生物技術基礎設施以及 Thermo Fisher Scientific、Takara Bio 和 New England BioLabs 等主要企業的強大影響力。

內切酶，又稱為“分子剪刀”，是重要的酶，能夠在DNA內部特定位點進行切割。它們是基因工程、重組DNA技術、診斷和治療研發中不可或缺的工具，構成了現代分子生物學和基因組編輯的基礎。市場成長主要受CRISPR應用、合成生物學和精準基因組學領域研發投入的增加以及基因治療臨床管線的不斷擴展所驅動。

市場動態

科技創新驅動研究活動

CRISPR-Cas基因編輯系統的興起徹底改變了分子生物學和生物技術。截至2025年初，已有超過150項臨床試驗正在探索基因編輯療法，推動了對精準內切酶的需求激增。更高的精準度和更低的脫靶效應使得CRISPR及類似核酸酶成為藥物研發和治療應用的關鍵工具。像 CRISPR Therapeutics 這樣的公司正在積極開發基於 CRISPR/Cas9 的療法，例如 CTX112，用於治療 CD19 陽性惡性腫瘤和自體免疫疾病，展現出巨大的商業潛力。

監理與倫理挑戰制約市場成長

關於人類基因組編輯的嚴格監管和倫理問題仍然是市場擴張的重大挑戰。諸如中國備受爭議的 "CRISPR 嬰兒" 事件等事件引發了全球關注，加強了審批框架，並延緩了商業化進程。這些監管措施增加了生技公司的營運複雜性，並延長了產品開發週期。

個人化醫療與精準基因體學的機會

全球對個人化醫療的日益關注正在為核酸內切酶市場創造豐厚的機會。核酸內切酶能夠實現精確的 DNA 修飾，從而支持客製化治療方案設計和基於基因的診斷。製藥公司與基因組學研究機構之間的合作正在加速這一轉變。例如，CRISPR Therapeutics 和 Vertex Pharmaceuticals 正在擴大合作，共同開發下一代基因療法，進一步將核酸內切酶整合到先進的醫療應用中。

轉型為基於 CRISPR 的診斷技術

診斷領域正迅速轉向利用 CRISPR 技術的檢測系統，例如 DETECTR 和 SHERLOCK。與 PCR 相比，這些技術具有更高的靈敏度、更快的檢測速度和更低的成本。利用 Cas12 和 Cas13 內切酶的 CRISPR 檢測方法目前用於即時病原體檢測、傳染病篩檢和精準診斷，在更廣泛的內切酶生態系統中開闢了一個高成長的區隔市場。

區隔市場洞察

依類型：

2024 年，特定內切酶區隔市場引領市場，這主要得益於它們在 CRISPR-Cas 和限制性內切酶技術中的重要作用。在這個區隔市場中，限制性內切酶和 CRISPR 核酸酶的需求量最大，尤其是在基因編輯研究領域。 GMP 級 Cas9 和 Cas12 酶現已成為細胞和基因治療生產中的標準組件。

依應用：

2024 年，基因組學和基因工程領域引領市場，這主要得益於它們在研究實驗室和臨床試驗中日益增長的應用。根據美國細胞與基因治療學會 (ASCTH) 的報告，到 2024 年，全球將有超過 4000 種基因、細胞和 RNA 療法正在研發中，這凸顯了核酸內切酶在基因組工程和驗證中的廣泛應用。預計研發領域將顯著成長，這主要得益於核酸酶在標靶驗證和生物標記鑑定中日益廣泛的應用。

資料來源：

到 2024 年，原核核酸內切酶將佔市場主導地位，佔酵素供應的大部分。其在合成生物學、克隆和分子診斷領域的廣泛應用正在推動該區隔市場的擴張。 Thermo Fisher Scientific 和 New England Biolabs 等公司提供全面的原核酶產品線，為大規模的學術和工業研究提供支援。

依最終使用者劃分：

到 2024 年，製藥和生技公司將佔最大的市場佔有率，這反映出生物製劑生產、基因編輯和治療藥物研發領域對核酸酶的需求不斷增長。 Intellia Therapeutics 和 CRISPR Therapeutics 等領先公司正在利用 Cas9 核酸酶作為其藥物發現流程的關鍵組成部分。同時，在政府和私人研究經費不斷增加的支持下，學術研究領域也穩定成長。

區域展望

北美：

北美引領全球市場，預計到 2024 年將達到 1.7 億美元，這得益於其完善的生物技術基礎設施和對基因組學研究的大量投入。美國是基於 CRISPR 技術的創新和治療開發的重要中心，例如安捷倫科技公司在 2023 年投資 7.25 億美元，用於擴大其在科羅拉多州的核酸生產能力。

歐洲：

歐洲在 2024 年佔第二大市場佔有率，預計到 2032 年將保持穩定成長。德國、瑞士和英國的創新集群正在推動基因組醫學的應用。歐盟精準醫療計畫的資金持續推動著區域市場的成長。

亞太地區：

亞太地區佔第三大市場佔有率，預計到 2032 年將實現最高的複合年增長率。中國、日本和印度等國家正在農業生物技術、臨床基因組學和診斷領域快速採用基因編輯工具。政府的策略支援和新興生物技術新創企業的湧現正在加速區域市場的滲透。

拉丁美洲與中東及非洲：

在生物技術研究投資增加和與國際製藥公司合作擴大的支持下，這些地區預計將經歷緩慢但穩定的成長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • DNA修飾技術進展
  • 基因工程技術進展
  • 主要公司新產品發布
  • 主要產業趨勢，包括併購和合作
  • 概述：基於CRISPR療法的關鍵新創公司

第五章：全球核酸內切酶市場分析、洞察與預測 (2019-2032)

  • 依類型劃分的市場分析、洞察與預測
    • 特異性核酸內切酶
      • 限制性內切酶
      • CRISPR-Cas 核酸酶
      • 其他
    • 非特異性核酸內切酶
      • DNA酶
      • RN酶
      • 其他
  • 依應用劃分的市場分析、洞察與預測
    • 基因體學與基因工程
    • 藥物發現與研究
    • 分子生物學
    • 其他
  • 依應用劃分的市場分析、洞察與預測來源
    • 原核生物
    • 真核生物
    • 其他
  • 市場分析、洞察與預測 - 依最終用戶劃分
    • 製藥和生技公司
    • 學術和研究機構
    • 其他
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美內切酶市場分析、洞察與預測，2019-2032

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲內切酶市場分析， 2019-2032 年內切酶市場分析、洞察與預測

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區內切酶市場分析、洞察與預測，2019-2032

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲內切酶市場分析、洞察與預測，2019-2032

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東和非洲內切酶市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
  • New England Biolabs
  • Promega Corporation
  • Thermo Fisher Scientific Inc.
  • Takara Bio Inc.
  • QIAGEN
  • Agilent Technologies Inc.
  • Merck KGaA
  • F. Hoffmann-La Roche Ltd
Product Code: FBI113905

Growth Factors of endonucleases Market

The global endonucleases market is demonstrating robust growth, fueled by accelerating advances in genomic research, gene-editing technologies, and personalized medicine. According to Fortune Business Insights, the market was valued at USD 357.1 million in 2024, is projected to reach USD 390.3 million in 2025, and is expected to rise significantly to USD 728.6 million by 2032, growing at a CAGR of 9.32% during the forecast period (2025-2032). North America led the market with a 47.61% share in 2024, supported by high R&D investments, advanced biotechnology infrastructure, and the strong presence of major players such as Thermo Fisher Scientific Inc., Takara Bio Inc., and New England Biolabs.

Endonucleases, often referred to as "molecular scissors," are crucial enzymes that cut DNA internally at specific sites. They are essential tools in genetic engineering, recombinant DNA technology, diagnostics, and therapeutic development, forming the foundation of modern molecular biology and genome editing. The market's growth is primarily driven by increasing research activity in CRISPR-based applications, synthetic biology, and precision genomics, alongside expanding clinical pipelines for gene therapies.

Market Dynamics

Technological Innovations Propel Research Activities

The rise of CRISPR-Cas gene-editing systems has revolutionized molecular biology and biotechnology. With over 150 active clinical trials exploring gene-editing therapies as of early 2025, demand for high-fidelity endonucleases has surged. Enhanced accuracy and reduced off-target effects have made CRISPR and similar nucleases indispensable in drug development and therapeutic applications. Companies like CRISPR Therapeutics are actively developing CRISPR/Cas9-based therapies, such as CTX112 for treating CD19+ malignancies and autoimmune diseases, signaling strong commercial potential.

Regulatory and Ethical Challenges Restrain Market Growth

Stringent regulations and ethical concerns regarding human genome modification remain significant challenges for market expansion. Events such as the controversial "CRISPR babies" case in China have led to global scrutiny, triggering tighter approval frameworks and delayed commercialization. These restrictions increase operational complexity for biotech firms and extend product development timelines.

Opportunities in Personalized Medicine and Precision Genomics

The growing global focus on personalized medicine is creating lucrative opportunities for the endonucleases market. By enabling precise DNA modification, endonucleases support customized therapeutic design and gene-based diagnostics. Collaborations between pharmaceutical companies and genomic research institutions are accelerating this transition. For example, CRISPR Therapeutics and Vertex Pharmaceuticals are expanding partnerships to develop next-generation gene therapies, reinforcing the integration of endonucleases into advanced medical applications.

Shift Toward CRISPR-based Diagnostics

The diagnostics landscape is shifting rapidly toward CRISPR-enabled detection systems, such as DETECTR and SHERLOCK. These technologies offer high sensitivity, faster results, and lower costs compared to PCR. CRISPR-based assays leveraging Cas12 and Cas13 endonucleases are now utilized for real-time pathogen detection, infectious disease screening, and precision diagnostics-creating a high-growth niche within the broader endonuclease ecosystem.

Segmentation Insights

By Type:

The specific endonucleases segment dominated the market in 2024, driven by their critical role in CRISPR-Cas and restriction enzyme technologies. Within this segment, restriction enzymes and CRISPR nucleases accounted for the largest demand, particularly in gene-editing research. Cas9 and Cas12 enzymes, available in GMP-grade forms, are now standard components in cell and gene therapy manufacturing.

By Application:

The genomics and genetic engineering segment led the market in 2024 due to growing adoption in research laboratories and clinical trials. The American Society of Cell & Gene Therapy reported that more than 4,000 gene, cell, and RNA therapies were in development globally as of 2024, highlighting the extensive utilization of endonucleases in genome manipulation and validation. The drug discovery and research segment is expected to show significant growth, driven by increasing use of nucleases in target validation and biomarker identification.

By Source:

In 2024, prokaryotic-derived endonucleases dominated the market, accounting for the majority of enzyme supply. Their broad application in synthetic biology, cloning, and molecular diagnostics has fueled segment expansion. Companies like Thermo Fisher Scientific Inc. and New England Biolabs offer comprehensive prokaryotic enzyme product lines that support large-scale academic and industrial research.

By End User:

Pharmaceutical and biotechnology companies held the largest market share in 2024, reflecting growing demand for nucleases in biologics production, gene editing, and therapeutic pipeline development. Major players such as Intellia Therapeutics and CRISPR Therapeutics utilize Cas9 nucleases as key components in drug discovery workflows. Meanwhile, academic and research institutes represent a steadily growing segment, supported by increasing government and private research funding.

Regional Outlook

North America:

North America dominated the global market in 2024, valued at USD 170.0 million, owing to its established biotechnology infrastructure and extensive funding for genomics research. The U.S. remains the primary hub for CRISPR-based innovation and therapeutic development, with companies like Agilent Technologies Inc. investing USD 725 million in 2023 to expand nucleic acid manufacturing capacity in Colorado.

Europe:

Europe accounted for the second-largest market share in 2024 and is projected to maintain steady growth through 2032. Innovation clusters in Germany, Switzerland, and the U.K. are leading genomic medicine adoption. The European Union's funding for precision medicine initiatives continues to boost the regional market.

Asia Pacific:

Asia Pacific ranks third in market share but is expected to record the fastest CAGR through 2032. Countries like China, Japan, and India are witnessing rapid adoption of gene-editing tools for agricultural biotechnology, clinical genomics, and diagnostics. Strategic government support and emerging biotech startups are accelerating regional market penetration.

Latin America and Middle East & Africa:

These regions are projected to experience moderate but consistent growth, supported by rising biotechnology research investments and expanding partnerships with international pharmaceutical firms.

Competitive Landscape and Key Developments

The market is semi-fragmented, featuring both established players and emerging biotech firms. Major companies-including Takara Bio Inc., Thermo Fisher Scientific Inc., and New England Biolabs-maintain dominance through broad product portfolios, strong academic partnerships, and extensive distribution networks. New entrants are focusing on CRISPR-based innovations, enzyme optimization, and regional market expansion.

Key Developments:

  • July 2025: New England Biolabs launched Monarch DNase I (lyophilized), optimized for removing genomic DNA contamination in RNA samples.
  • May 2025: Biomay AG introduced an FDA-grade CRISPR/Cas9 nuclease for genome-editing applications.
  • January 2023: Aldevron LLC launched Eureca-V Nuclease for diagnostic, therapeutic, and agricultural workflows.
  • January 2020: ERS Genomics Limited partnered with New England Biolabs to commercialize CRISPR-based tools and reagents.

Conclusion

The global endonucleases market is poised for substantial expansion from USD 390.3 million in 2025 to USD 728.6 million by 2032, driven by rapid progress in CRISPR gene editing, synthetic biology, and personalized medicine. North America will continue to dominate, while Asia Pacific emerges as the fastest-growing region. With ongoing advancements in enzyme engineering, therapeutic development, and precision diagnostics, endonucleases are set to remain a cornerstone of the global biotechnology revolution.

Segmentation By Type

  • Specific Endonucleases
    • Restriction Enzymes
    • CRISPR-Cas Nucleases
    • Others
  • Non-specific Endonucleases
    • DNases
    • RNases
    • Others

By Application

  • Genomics & Genetic Engineering
  • Drug Discovery & Research
  • Molecular Biology
  • Others

By Source

  • Prokaryotic
  • Eukaryotic
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic & Research Institutes
  • Others

By Geography

  • North America (By Type, Application, Source, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Application, Source, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Application, Source, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Application, Source, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Application, Source, End User, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Technological Advancements in DNA Modification Techniques
  • 4.2. Technological Advancements in Genetic Engineering
  • 4.3. New Product Launches, By Key Players
  • 4.4. Key Industry Developments Such as Mergers, Acquisitions, and Collaborations
  • 4.5. Overview: Key Start-ups in CRISPR-based Therapeutics

5. Global Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Specific Endonucleases
      • 5.1.1.1. Restriction enzymes
      • 5.1.1.2. CRISPR-Cas nucleases
      • 5.1.1.3. Others
    • 5.1.2. Non-specific Endonucleases
      • 5.1.2.1. DNases
      • 5.1.2.2. RNases
      • 5.1.2.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Genomics & Genetic Engineering
    • 5.2.2. Drug Discovery & Research
    • 5.2.3. Molecular Biology
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Source
    • 5.3.1. Prokaryotic
    • 5.3.2. Eukaryotic
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Pharmaceutical and Biotechnology Companies
    • 5.4.2. Academic & Research Institutes
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Specific Endonucleases
      • 6.1.1.1. Restriction enzymes
      • 6.1.1.2. CRISPR-Cas nucleases
      • 6.1.1.3. Others
    • 6.1.2. Non-specific Endonucleases
      • 6.1.2.1. DNases
      • 6.1.2.2. RNases
      • 6.1.2.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Genomics & Genetic Engineering
    • 6.2.2. Drug Discovery & Research
    • 6.2.3. Molecular Biology
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Source
    • 6.3.1. Prokaryotic
    • 6.3.2. Eukaryotic
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Pharmaceutical and Biotechnology Companies
    • 6.4.2. Academic & Research Institutes
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Specific Endonucleases
      • 7.1.1.1. Restriction enzymes
      • 7.1.1.2. CRISPR-Cas nucleases
      • 7.1.1.3. Others
    • 7.1.2. Non-specific Endonucleases
      • 7.1.2.1. DNases
      • 7.1.2.2. RNases
      • 7.1.2.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Genomics & Genetic Engineering
    • 7.2.2. Drug Discovery & Research
    • 7.2.3. Molecular Biology
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Source
    • 7.3.1. Prokaryotic
    • 7.3.2. Eukaryotic
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Pharmaceutical and Biotechnology Companies
    • 7.4.2. Academic & Research Institutes
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Specific Endonucleases
      • 8.1.1.1. Restriction enzymes
      • 8.1.1.2. CRISPR-Cas nucleases
      • 8.1.1.3. Others
    • 8.1.2. Non-specific Endonucleases
      • 8.1.2.1. DNases
      • 8.1.2.2. RNases
      • 8.1.2.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Genomics & Genetic Engineering
    • 8.2.2. Drug Discovery & Research
    • 8.2.3. Molecular Biology
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Source
    • 8.3.1. Prokaryotic
    • 8.3.2. Eukaryotic
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Pharmaceutical and Biotechnology Companies
    • 8.4.2. Academic & Research Institutes
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Specific Endonucleases
      • 9.1.1.1. Restriction enzymes
      • 9.1.1.2. CRISPR-Cas nucleases
      • 9.1.1.3. Others
    • 9.1.2. Non-specific Endonucleases
      • 9.1.2.1. DNases
      • 9.1.2.2. RNases
      • 9.1.2.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Genomics & Genetic Engineering
    • 9.2.2. Drug Discovery & Research
    • 9.2.3. Molecular Biology
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Source
    • 9.3.1. Prokaryotic
    • 9.3.2. Eukaryotic
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Pharmaceutical and Biotechnology Companies
    • 9.4.2. Academic & Research Institutes
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Endonucleases Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Specific Endonucleases
      • 10.1.1.1. Restriction enzymes
      • 10.1.1.2. CRISPR-Cas nucleases
      • 10.1.1.3. Others
    • 10.1.2. Non-specific Endonucleases
      • 10.1.2.1. DNases
      • 10.1.2.2. RNases
      • 10.1.2.3. Others
  • 10.2. Market Analysis, Insights and Forecast - By Application
    • 10.2.1. Genomics & Genetic Engineering
    • 10.2.2. Drug Discovery & Research
    • 10.2.3. Molecular Biology
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Source
    • 10.3.1. Prokaryotic
    • 10.3.2. Eukaryotic
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Pharmaceutical and Biotechnology Companies
    • 10.4.2. Academic & Research Institutes
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. New England Biolabs
    • 11.2.2. Promega Corporation
    • 11.2.3. Thermo Fisher Scientific Inc.
    • 11.2.4. Takara Bio Inc.
    • 11.2.5. QIAGEN
    • 11.2.6. Agilent Technologies Inc.
    • 11.2.7. Merck KGaA
    • 11.2.8. F. Hoffmann-La Roche Ltd

List of Tables

  • Table 1: Global Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 2: Global Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 3: Global Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 4: Global Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 5: Global Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 6: Global Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 7: Global Endonucleases Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 8: North America Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 9: North America Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 10: North America Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 11: North America Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 12: North America Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 13: North America Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 14: North America Endonucleases Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 15: Europe Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 16: Europe Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 17: Europe Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 18: Europe Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 19: Europe Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 20: Europe Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 21: Europe Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 22: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 23: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 24: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 25: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 26: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 27: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 28: Asia Pacific Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 29: Latin America Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 30: Latin America Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 31: Latin America Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 32: Latin America Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 33: Latin America Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 34: Latin America Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 35: Latin America Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 36: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Type, 2019-2032
  • Table 37: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Specific Endonucleases, 2019-2032
  • Table 38: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Non-specific Endonucleases, 2019-2032
  • Table 39: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 40: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by Source, 2019-2032
  • Table 41: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 42: Middle East & Africa Endonucleases Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Endonucleases Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Endonucleases Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Endonucleases Market Value Share (%), by Application, 2024 & 2032
  • Figure 4: Global Endonucleases Market Value Share (%), by Source, 2024 & 2032
  • Figure 5: Global Endonucleases Market Value Share (%), by End User, 2024 & 2032
  • Figure 6: Global Endonucleases Market Value (USD million), by Region, 2024 & 2032
  • Figure 7: North America Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 8: North America Endonucleases Market Value Share (%), by Type, 2024
  • Figure 9: North America Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 10: North America Endonucleases Market Value Share (%), by Application, 2024
  • Figure 11: North America Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 12: North America Endonucleases Market Value Share (%), by Source, 2024
  • Figure 13: North America Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 14: North America Endonucleases Market Value Share (%), by End User, 2024
  • Figure 15: North America Endonucleases Market Value (USD million), By Country, 2024 & 2032
  • Figure 16: North America Endonucleases Market Value Share (%), By Country, 2024
  • Figure 17: Europe Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 18: Europe Endonucleases Market Value Share (%), by Type, 2024
  • Figure 19: Europe Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 20: Europe Endonucleases Market Value Share (%), by Application, 2024
  • Figure 21: Europe Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 22: Europe Endonucleases Market Value Share (%), by Source, 2024
  • Figure 23: Europe Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 24: Europe Endonucleases Market Value Share (%), by End User, 2024
  • Figure 25: Europe Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 28: Asia Pacific Endonucleases Market Value Share (%), by Type, 2024
  • Figure 29: Asia Pacific Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 30: Asia Pacific Endonucleases Market Value Share (%), by Application, 2024
  • Figure 31: Asia Pacific Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 32: Asia Pacific Endonucleases Market Value Share (%), by Source, 2024
  • Figure 33: Asia Pacific Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 34: Asia Pacific Endonucleases Market Value Share (%), by End User, 2024
  • Figure 35: Asia Pacific Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 38: Latin America Endonucleases Market Value Share (%), by Type, 2024
  • Figure 39: Latin America Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 40: Latin America Endonucleases Market Value Share (%), by Application, 2024
  • Figure 41: Latin America Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 42: Latin America Endonucleases Market Value Share (%), by Source, 2024
  • Figure 43: Latin America Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 44: Latin America Endonucleases Market Value Share (%), by End User, 2024
  • Figure 45: Latin America Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Endonucleases Market Value (USD million), by Type, 2024 & 2032
  • Figure 48: Middle East & Africa Endonucleases Market Value Share (%), by Type, 2024
  • Figure 49: Middle East & Africa Endonucleases Market Value (USD million), by Application, 2024 & 2032
  • Figure 50: Middle East & Africa Endonucleases Market Value Share (%), by Application, 2024
  • Figure 51: Middle East & Africa Endonucleases Market Value (USD million), by Source, 2024 & 2032
  • Figure 52: Middle East & Africa Endonucleases Market Value Share (%), by Source, 2024
  • Figure 53: Middle East & Africa Endonucleases Market Value (USD million), by End User, 2024 & 2032
  • Figure 54: Middle East & Africa Endonucleases Market Value Share (%), by End User, 2024
  • Figure 55: Middle East & Africa Endonucleases Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Endonucleases Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Endonucleases Market Share (%), By Company, 2024